uniQure N.V (UQ1) - Total Liabilities
Based on the latest financial reports, uniQure N.V (UQ1) has total liabilities worth €629.36 Million EUR (≈ $735.79 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore UQ1 net asset momentum to track the company's year-over-year net asset growth rate.
uniQure N.V - Total Liabilities Trend (2016–2025)
This chart illustrates how uniQure N.V's total liabilities have evolved over time, based on quarterly financial data. See UQ1 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
uniQure N.V Competitors by Total Liabilities
The table below lists competitors of uniQure N.V ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Paramount Group Inc
NYSE:PGRE
|
USA | $3.90 Billion |
|
MY EG Services Bhd
KLSE:0138
|
Malaysia | RM1.83 Billion |
|
The Wendy’s Co
NASDAQ:WEN
|
USA | $4.84 Billion |
|
Northking Information Technology Co
SHE:002987
|
China | CN¥586.97 Million |
|
Great Wall Enterprise Co Ltd
TW:1210
|
Taiwan | NT$40.68 Billion |
|
Resilient Property Income Fund Ltd
JSE:RES
|
South Africa | ZAC15.01 Billion |
|
Jinlongyu Group Co Ltd Class A
SHE:002882
|
China | CN¥2.58 Billion |
|
Dar Global Plc
LSE:DAR
|
UK | $1.48 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down uniQure N.V's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see uniQure N.V market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 4.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.81 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how uniQure N.V's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for uniQure N.V (2016–2025)
The table below shows the annual total liabilities of uniQure N.V from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €626.01 Million ≈ $731.87 Million |
+11.13% |
| 2024-12-31 | €563.29 Million ≈ $658.54 Million |
-9.73% |
| 2023-12-31 | €624.02 Million ≈ $729.54 Million |
+172.55% |
| 2022-12-31 | €228.96 Million ≈ $267.67 Million |
+7.29% |
| 2021-12-31 | €213.40 Million ≈ $249.49 Million |
+121.17% |
| 2020-12-31 | €96.49 Million ≈ $112.81 Million |
-23.16% |
| 2019-12-31 | €125.57 Million ≈ $146.81 Million |
+33.16% |
| 2018-12-31 | €94.30 Million ≈ $110.25 Million |
-21.60% |
| 2017-12-31 | €120.28 Million ≈ $140.63 Million |
-5.01% |
| 2016-12-31 | €126.63 Million ≈ $148.05 Million |
-- |
About uniQure N.V
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. Th… Read more